Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
HEIDELBERG, Germany, Nov. 09, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016 at 4:00 p.m. (GMT) in London.
A live webcast of the conference presentation can be accessed through the “Events” section on the “Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact: Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail: [email protected] or [email protected] Media Contact: Anca Alexandru, Head of Communications, EU IR Phone: +49 6221 64793341 E-Mail: [email protected]
